Similarly, CK treatment attenuated chronic cerebral hypoperfusion (CCH)-induced Aβ1–42 deposition and ameliorated cognition impairment in vascular-dementia rats by upregulating the expression of both pSer9-glycogen synthase kinase 3β (pSer9-GSK3β) and insulin-degrading enzyme (IDE), which are responsible for the production and clearance of Aβ1–42 [182]. Here, IDE is linked to vascular dementia.